Cardiometabolic Profiles and Treatment Trajectories of <scp>GLP</scp> ‐1 Receptor Agonist Users With Obstructive Sleep Apnea: Real‐World Evidence From a Large Private Healthcare Cohort in Poland

The authors declare no conflicts of interest. Data are available on reasonable request made to the corresponding author. The data are not publicly available due to institutional policies. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70644. Table S1: Baseline characteristics of study participants according to GLP-1 receptor agonist use. Figure S1: Annual prevalence of GLP-1 receptor agonist use among patients with newly diagnosed obstructive sleep apnea. Figure S2: Adjusted temporal trends in GLP-1 receptor agonist use among patients with incident obstructive sleep apnea. Figure S3: Quarterly prevalence of GLP-1 receptor agonist use among patients with newly diagnosed obstructive sleep apnea. Figure S4: Adjusted within-year patterns of GLP-1 receptor agonist use in incident OSA. Figure S5: Discrimination of predictive models for GLP-1 receptor agonist use in patients with obstructive sleep apnea. Figure S6: Adjusted restricted cubic spline analysis of BMI and GLP-1 use. Figure S7: Effect modification of the association between body mass index and GLP-1 receptor agonist use by sex and type 2 diabetes status. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.